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ABSTRACT: Cationic liposomes prepared from dimethyldioctadecylammonium bromide (DDAB) and trehalose 6,6′-
dibehenate (TDB) are strong liposomal adjuvants. As with many liposome formulations, within the laboratory DDAB:TDB is
commonly prepared by the thin-ﬁlm method, which is diﬃcult to scale-up and gives high batch-to-batch variability. In contrast,
controllable technologies such as microﬂuidics oﬀer robust, continuous, and scale-independent production. Therefore, within
this study, we have developed a microﬂuidic production method for cationic liposomal adjuvants that is scale-independent and
produces liposomal adjuvants with analogous biodistribution and immunogenicity compared to those produced by the small-
scale lipid hydration method. Subsequently, we further developed the DDAB:TDB adjuvant system to include a lymphatic
targeting strategy using microﬂuidics. By exploiting a biotin−avidin complexation strategy, we were able to manipulate the
pharmacokinetic proﬁle and enhance targeting and retention of DDAB:TDB and antigen within the lymph nodes. Interestingly,
redirecting these cationic liposomal adjuvants did not translate into notably improved vaccine eﬃcacy.
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1. INTRODUCTION
Liposomes have been extensively studied as vaccine adjuvants.
However, current production methods for liposomes are costly,
multistep, and generally limited to batch production. Given that
the cost of vaccines is a key contributing factor in global
accessibility, low-cost scalable production of vaccine adjuvants is
required to ensure an aﬀordable supply chain. To address this
and bring down the costs of liposomal adjuvants, streamlining
their manufacturing process is essential. Recently, the
application of microﬂuidics has been demonstrated for a range
of nanoparticles and liposomes (e.g., see refs 1−5). Micro-
ﬂuidics as a manufacturing platform oﬀers a scale-independent
alternative to batch production; the nanoparticle product
attributes have been shown to be process-controlled in terms
of particle size, and high protein loading can be achieved
compared to other production methods.1
In the manufacture of liposomal adjuvants, control of the
physicochemical attributes is vital given that these are often
critical quality attributes. Indeed, a range physicochemical
attributes have been shown to impact on the immunological
properties of liposomal adjuvants, including particle size,6−9
charge,10−12 lipid composition,11,13,14 ﬂuidity,14−17 and degree
of pegylation.18−21 Furthermore, several of these physicochem-
ical attributes also dictate the pharmacokinetic properties of
both the liposomal adjuvant and the subunit antigen and the
recruitment of antigen presenting cells (APCs) to the injection
site.8 Thus, by modifying these attributes, both the pharmaco-
kinetic and immunogenic proﬁle can be manipulated. In
particular, the use of cationic lipids has a strong impact on
both the adjuvanticity of liposomes and their retention at the site
of injection. For example, the use of the cationic lipid N,N′-
dimethyl-N,N′-dioctadecylammonium bromide (DDAB) has
been shown to favor the absorption of subunit antigens onto the
liposomal surface, promote retention of both the adjuvant and
antigen at the injection site, and promote strong cell-mediated
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immune responses.10 To formulate liposomal adjuvants, DDAB
is often used in combination with the synthetic immunopo-
tentiator α,α′-trehalose-6,6′-dibehenate (TDB) to improve the
stability of the liposomes and enhance the immunogenicity of
the formulation.22 TDB is a synthetic analogue of trehalose 6,6′-
dimycolate (TDM), a mycolic acid from the mycobacterial cell
wall from Mycobacterium tuberculosis, and it is combined with
DDAB at a weight ratio of 5:1 (DDAB:TDB).22 The
adjuvanticity of DDAB:TDB is generated via the Syk−Card9−
Bcl10−Malt1 pathway. In this way, TDB activates macrophages
and dendritic cells (DCs).23 Moreover, interaction with the
Mincle receptor (a C-type lectin receptor expressed in
macrophages) which also stimulates MyD88-dependent Th1/
Th17 responses may contribute to DDAB:TDB eﬃcacy.24,25
Through this pathway, DDAB:TDB promotes strong cellular
and humoral immune responses based on high IFN-γ and IL-17
secretion, low IL-5 production, and high IgG antibody
production.26,27 The pharmacokinetic proﬁle of DDAB:TDB
and numerous variants has also been investigated to consider
potential links between biodistribution and vaccine eﬃcacy. By
dual radiolabeling of the adjuvant and the antigen, it has been
shown that cationic liposomes form a depot at the injection site,
followed by a sustained release to the draining lymph nodes.15,28
However, it has also been shown that direct injection of
DDAB:TDB into the lymph node promotes a strong response.29
Indeed, Mohanan et al. showed the importance of the route of
administration for the DDAB:TDB liposomal formulation;
while no signiﬁcant diﬀerences were found between subcuta-
neous, intramuscular, or intradermal vaccination, intralymphatic
administration of DDAB:TDB liposomes resulted in signiﬁ-
cantly higher IgG2a and IFN-γ responses.29 Thus, the potential
to redirect an increased dose of DDAB:TDB to the draining
lymphatics and further enhance immune responses is an
interesting consideration. To promote retention at the draining
lymphatics, a biotin−avidin complex formulation can be
adopted. Studies carried out by Phillips et al.30 demonstrated
the ability of this high-aﬃnity complex to improve the
accumulation and retention of liposomes into the draining
lymph nodes. By this means injection of biotin-coated
liposomes, in combination with an adjacent intramuscular
injection of avidin, become localized/trapped in the draining
lymph nodes because of the formation of avidin−biotin-coated
liposome complexes.30,31 Thus, exploiting the high aﬃnity
between biotin and avidin resulted in higher accumulation of
liposomes in the lymph nodes (up to 14%) in comparison to
biotin-coated liposomes injected without avidin (2% of the
injected dose).30
As with many liposome formulations, the common method
for preparing DDAB:TDB liposomal adjuvants within the
laboratory is via the hydration method (LH),22,32 which results
in the formation of large multilamellar vesicles (MLVs) which
are heterogeneous in nature. In order to reduce the size and
lamellarity of these liposomes, sonication or high-shear mixing
can be applied. This produces small unilamellar vesicles (SUVs),
and in the case of DDAB:TDB, this can reduce the particle size
from approximately 500 to 200 nm and a polydispersity (PDI)
between 0.2 and 0.4.17,32 However, these processes are diﬃcult
to scale-up and are generally limited to small-scale laboratory
production. Therefore, to address the need for scale-
independent manufacture of cationic liposomal adjuvants, we
have investigated the use of microﬂuidics for the production of
DDAB:TDB. We have then applied this method to develop a
modiﬁed biotinylated DDAB:TDB formulation that can
promote liposome and antigen drainage to, and retention
within, the lymphatics in order to test the impact this has on
vaccine eﬃcacy.
2. MATERIALS AND METHODS
2.1. Materials. The cationic surfactant dimethyldioctadecy-
lammonium (DDAB) bromide, the immunopotentiator treha-
lose 6,6′-dibehenate (TDB), and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000]
(DSPE-PEG(2000)-biotin) were purchased from Avanti Polar
Lipids Inc. (Alabaster, United States). Avidin (egg white) and
cholesterol were purchased from Sigma-Aldrich Company Ltd.
(Poole, U.K.). Hybrid 56 (H56) tuberculosis vaccine candidate
was gifted by Statens Serum Institut (Copenhagen, Denmark).
Tris-base was obtained from IDN Biomedical Inc. (Aurora, OH,
United States) and used to make 10 mM Tris buﬀer and
adjusted to pH 7.4 using HCl. The radionucleotides iodine 125I
(NaI in NaOH solution) and tritium 3H-cholesterol (tritium-
labeled cholesterol in ethanol) and Ultima Gold scintillation
ﬂuid were purchased from PerkinElmer (Waltham, MA, United
States). Sodium hydroxide (NaOH) and hydrogen peroxide
(H2O2) were purchased from Sigma-Aldrich Company Ltd.
(Poole, U.K.). Bicinchoninic acid protein assay (BCA) kit and
Sephadex G-75 superﬁne were purchased from Fisher Scientiﬁc
(Leicestershire, U.K.). IODO-GEN precoated iodination tubes
from Pierce Biotechnology (Rockford, IL) and scintillation vials
from Sardsted Ltd. (Leicester, U.K.) were used. Horseradish
peroxidase (HRP) enzyme (HRP-streptavidin), puriﬁed rat anti
mouse IFN-γ and IL-17, biotin conjugates IFN-γ and IL-17, IL-
17 standard, and mouse IL-5 ELISA set were purchased from
Becton Dickinson (BD biosciences, New Jersey, United States).
Mercaptoethanol, concanavalinA (conA), Tween 20, Bovine
serum albumin (BSA), carbonate-bicarbonate buﬀer tablets,
sulfuric acid, IFN-γ standard, skimmed milk powder, heparin,
bovine serum albumin, sodium chloride (NaCl), sodium azide
(NaN3), Triton X-100, and protease inhibitor cocktail were
purchased from Sigma-Aldrich Company Ltd. (Poole, U.K.).
Tetramethylbenzidine (TMB) substrate, isotype-speciﬁc im-
munoglobulins (Goat antimouse IgG1 and IgG2c), Penicillin-
Streptomycine (10 000 U/mL), L-glutamine 200 mM, sodium
pyruvate 100 mM, MEM nonessential amino acids solution
(100×), RPMI 1640 media, fetal bovine serum (FBS), HEPES
(1 M), and phosphate buﬀered saline (10×) were purchased
from Fisher Scientiﬁc - UK Ltd. (Loughborough, U.K.).
2.2. Manufacture of Liposomes. Two techniques for the
production of liposomes were applied and compared: LH and
microﬂuidics (MF). For the LH method, liposomes were
prepared by a modiﬁcation of the Bangham method.33 Brieﬂy,
lipid stocks of DDAB and TDB were dissolved in a mixture of
chloroform and methanol (9:1 v/v). The required amount of
lipid solution was transferred to a round-bottom ﬂask to reach
the appropriate ﬁnal concentration (5 mg/mL DDA and 1 mg/
mL TDB). Organic solvent was removed under vacuum with a
rotary evaporator for 15 min at 200 rpm (rpm). The lipid ﬁlm
was hydrated with the desired amount of 10 mMTris buﬀer (pH
7.4) at 60 °C for 20−30 min.
The preparation of liposomes by microﬂuidics was conducted
on the Nanoassemblr Benchtop system from Precision Nano-
systems Inc. Stocks of DDAB and TDB were prepared in 2-
propanol (IPA) and mixed to the desired concentration (in
general 20 mg/mL of DDAB and 2 mg/mL TDB). Selected
speeds (total ﬂow rates (TFRs)) and ratios between the aqueous
and organic phase (ﬂow rate ratios (FRRs)) were investigated,
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with FRRs of 1:1, 3:1, and 5:1 (solvent to aqueous phase) and
TFRs of 5, 10, and 15 mL/min tested. During the process,
samples were heated to ensure the lipids stayed dissolved and
thus the heating block was set at 60 °C. To prepare biotinylated
liposomes, DSPE-PEG(2000)-biotin was added to the
DDAB:TDB formulation at a 20 mol % ratio in order to
investigate the eﬀect of the biotin−avidin complex in the
distribution of these particulate systems within the body.
Concentrations ranging primarily between 0.3 and 24 mg/mL
total lipid were tested. H56 antigen (5 μg per vaccine dose (50
μL)) was mixed with preformed liposomes after production.
Solvent was removed by dialysis (dialysis tubing Mw 12 000−
14 000 Da, Sigma-Aldrich, Poole, U.K.) against Tris buﬀer. For
free-antigen removal, a 300 000 Da MWCO membrane was
used (Spectra-Por, Spectrum Laboratories, Breda, The Nether-
lands).
2.3. Determination of the Particle Size, PDI, and Zeta
Potential. The size of liposomes was determined by dynamic
light scattering (Zetasizer nano ZS, Malvern PANalytical Ltd.,
Worcestershire, U.K.). Samples manufactured using the LH
were measured approximately 1 h after preparation to allow
samples to cool down, whereas the samples manufactured using
microﬂuidics were measured directly after puriﬁcation. For zeta
potential measurement, samples were diluted in the same
fashion as for the size determination. Three measurements of
each sample at 25 °C were taken.
2.4. Quantiﬁcation of Lipid Recovery. Quantiﬁcation of
the lipid recovery was performed by high-performance liquid
chromatography (HPLC, YL Instruments Co. Ltd. Korea) using
a Sedex 90LTD ELSD detector (Sedex Sedere, Alfortville,
France) as described previously.34 A Luna 5 μ C18(2) column
(Phenomenex, Cheshire, U.K.), pore size of 100 Å, was used.
Lipids were dissolved in chloroform:methanol (9:1 v/v), and
liposomal samples were injected without preparation. HPLC-
ELSD settings were kept constant as follows: 30 μL injection
volume in a partial loopﬁll injection mode, 100 μL loop volume,
and 15 μL tubing volume. Column temperature was maintained
at 35 °C, whereas the ELSD temperature was set at 52 °C in all
the runs. Nitrogen was used as a carrier gas at 3.5 psi inlet
pressure. Clarity DataApex version 4.0.3.876 was used for data
analysis.
2.5. Quantiﬁcation of Antigen Loading. Quantiﬁcation
of the antigen loading on the liposomal formulations was
performed by reverse phase HPLC (RP-HPLC) using an
ultraviolet (UV) detector (Agilent Technologies, Edinburgh,
U.K.) as described previously.35 A Jupiter 5 μ C18(2) column
(Phenomenex, Cheshire, U.K.), pore size 300 Å, was used as
stationary phase. For the preparation of the standards and
samples, antigen alone or liposomes loaded with H56 were
diluted in 50% Tris/IPA (1:1 v/v).36 Mobile phase A contained
90% H2O, 10% acetonitrile, and 0.1% TFA, whereas mobile
phase B contained 70% acetonitrile, 30% H2O, and 0.1% TFA.
The instrument settings were as follows: 50 μL injection volume,
ﬂow rate 1 mL/min, UV wavelength 210 nm, and column
temperature 60 °C.
2.6. Stability of Liposomes in Simulated in Vivo
Conditions. Stability of the antigen-loaded liposomal for-
mulations was assessed in terms of size, PDI, and zeta potential
under simulated in vivo conditions. Brieﬂy, liposomes were
placed in a water bath at 37 °C with 50% FBS, and aliquots were
taken at speciﬁc time points in line with the biodistribution time
points.
2.7. In Vivo Studies. All in vivo studies were conducted
under the regulations of Directive 2010/63/EU. All protocols
have been subjected to ethical review and were carried out in a
designated establishment. During all studies, mice were weighed
weekly and examined to detect any signiﬁcant change in their
health. All mice had a healthy weight, characteristic of the strain
and age, with no signiﬁcant diﬀerences between groups.
2.7.1. Biodistribution Studies of Liposomal Adjuvants and
Their Associated Antigen. Inbred female BALB/Cmice (3mice
per time point) were obtained from the Biological Procedure
Unit at the University of Strathclyde, Glasgow. All mice used
were 6−10 weeks of age at the start of the experiment.
Liposomal formulations were radiolabeled with 3H-Cholesterol
by incorporation of the isotope into the lipid bilayer.37 For
isotonicity, 10% w/v trehalose was added to the ﬁltered buﬀer
(0.22 μm ﬁlter). Radiolabeled H56 antigen was added to the
hydrated formulation at the desired concentration (0.1 mg/mL)
for surface loading onto the DDAB:TDB formulation. This
formulation was used as a control because its biodistribution
vaccine eﬃcacy has been reported previously.8,10,11,13,18,38 All
liposomal formulations contained a ﬁnal concentration of 250
μg DDAB/50 μg TDB/5 μg H56 per vaccine dose (50 μL). To
investigate the eﬀect of the biotin−avidin complex in the
distribution of these DDAB:TDB liposomes, DSPE-PEG(2000)
biotin was added to the DDAB:TDB formulation at a 20 mol %
ratio. When necessary, avidin (200 μg per dose) was injected
intramuscularly 2 h prior to main immunization with the
biotinylated formulation in the same quadriceps (adjacent
injections).30
Mice were injected intramuscularly with 50 μL of the
radiolabeled formulation in the right quadriceps, and mice
were terminated after 6, 24, 48, 96, and 192 h. Speciﬁc organs
and tissues were isolated: inguinal lymph node (ILN),
mesenteric lymph node (MLN), popliteal lymph node (POP),
spleen, and the site of injection. These organs and tissues were
added to a scintillation vial containing 2 mL of NaOH 10 mM
for dissolution. Mice carcasses were dissolved with 60 mL of
NaOH 10 mM for mass balance calculation. All vials containing
NaOH were incubated in an oven at 60 °C overnight. All
scintillation vials containing 2 mL of either carcasses, organs, or
tissues were bleached with 200 μL of H2O2 and incubated for 2 h
in the oven at 60 °C.
2.7.2. Immunization Studies. Five female C57BL/6 mice
(6−10 week-old) per group were injected i.m. (50 μL) into the
right quadriceps. Mice received 3 immunizations at 2 week
intervals (days 0, 14, and 28) and were terminated 3 weeks after
the last immunization (on day 49). For the quantiﬁcation of
serum immunoglobulins, 50 μL of blood was collected via tail-
bleed on days 7, 21, and 49. Blood was collected in a heparinized
Eppendorf (1% w/v heparin) and centrifuged for 10 min at
10 000 g (Mini centrifuge Mikro200, Hettich (Tuttlingen,
Germany)) in order to separate blood cells from serum. A
standard direct enzyme-linked immunosorbent assay (ELISA)
was carried out to detect immunoglobulins IgG1 and IgG2c in
serum. Maxisorp ﬂat bottom 96-well plates (Fisher Scientiﬁc,
Loughborough, U.K.) (high binding and aﬃnity) were coated by
passive absorption overnight at 4 °C with 0.5 μg/mL H56
antigen diluted in carbonate buﬀer 0.05 N pH 9.6 (100 μL/
well). Plates were washed with washing buﬀer (PBS pH 7.2, 10
mM containing 0.2% Tween 20) and blocked for 1.5−2 h at
room temperature with 200 μL/well of PBS (pH 7.2, 10 mM)
containing 2% BSA to block any nonspeciﬁc binding. Samples
were added to the plates (serial dilution). Plates were then
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incubated at room temperature for 2 h. HRP-conjugated
antibody was diluted in 1% BSA in PBS (1:20000 and 1:5000
for IgG1 and IgG2c, respectively) and added in a volume of 100
μL/well to the washed plates. Plates were incubated for an hour,
and TMB substrate was added to the plates at 100 μL/well. The
reaction was stopped by adding 0.2 M sulfuric acid, and the
absorbance at 450 nm was measured (with wavelength
correction 570/620 nm). Results were plotted as the Log10 of
the end point titer giving an optical density value (OD450) of 0.1
or higher.
Spleens and popliteal lymph nodes from each mouse were
isolated and processed on day 49 as described before.35 Cells
were counted and diluted in complete RPMI to a ﬁnal
concentration of 2 × 106 cells/mL and plated (100 μL) on a
Nunclon 96-well round-bottom (Fisher scientiﬁc, Lough-
borough, U.K.). Cells were stimulated with 100 μL of ConA
(5 μg/mL), RPMI media, or H56 antigen (5 μg/mL) and
incubated at 37 °C, 5% CO2, and 95% humidity for 72 h.
Supernatants were harvested and stored at −20 °C for further
processing. The sites of injection (i.e., the right quadriceps) were
excised 3 weeks after the last immunization (on day 49), and the
method from Sharp et al. for the analysis of cytokines at the site
of injection was followed.39 Quadriceps muscles were removed
from the bone and weighed out individually. Individual muscles
were homogenized in 2.5 mL of homogenization buﬀer 500 mM
NaCl/50 mM Hepes, pH 7.4 containing 0.1% Triton X-100,
0.02% NaN3, and 1% v/v protease inhibitor cocktail.
Homogenates were sonicated twice for 15 s and centrifuged at
3600 rpm for 20 min at 4 °C. The supernatants were removed
and stored at −20 °C.
Supernatants from restimulated splenocytes and lymph nodes
were analyzed using a sandwich ELISA protocol for the
production of cytokines IL-17 and IFN-γ. Plates were coated
with the speciﬁc capture antibody diluted in carbonate buﬀer,
overnight at 4 °C. Plates were blocked for 1.5−2 h at room
temperature with PBS containing 2% milk powder. Samples and
standards were diluted in 2% BSA in PBS and incubated at room
temperature for 2 h. Then the biotin conjugate was diluted in 1%
BSA in PBS (IL-17 1:2000, IFN-γ 1:5000), and 100 μL were
added on each well. Plates were incubated for an hour at room
temperature followed by incubation with 100 μL/well of HRP-
streptavidin in 1% BSA (1:5000). TMB substrate was added to
the plates (100 μL/well), and after approximately 15 min the
reaction was stopped with 0.2 M sulfuric acid. For the
quantiﬁcation of IL-5 cytokine production, the manufacturer’s
instructions were followed (ELISA IL-5 kit, BD Biosciences). All
experiments were carried out in duplicate, and absorbance was
measured at 450 nm with wavelength correction (570/620 nm).
2.8. Statistical Analysis.All experiments were carried out at
least in triplicate unless otherwise stated. Means and standard
deviations are plotted on the graphs. Statistical analysis of data
was calculated by one-way analysis of variance (ANOVA).
Where signiﬁcant diﬀerences are indicated, diﬀerences between
means were determined by Tukey’s post hoc test.
3. RESULTS AND DISCUSSION
3.1. Production and Optimization of DDAB:TDB
Liposomes Using Microﬂuidics. The use of microﬂuidics
as a technique for the production of liposomes has already been
demonstrated in several studies with process parameters,
Figure 1. Establishing the operating parameters for DDAB:TDB using microﬂuidics. The eﬀect of lipid concentration on the physicochemical
characteristics of the DDAB:TDB adjuvant formulations manufactured using microﬂuidics. DDAB:TDB liposomes were prepared at TFR 10 mL/min
and FRR 3:1, varying the initial concentration from 0.3 to 24mg/mL, and (A) particle size, (B) PDI, and (C) zeta potential weremeasured. The impact
of the diﬀerent parameters adopted during microﬂuidics formulation of DDAB:TDB liposomes was tested [(D) particle size (bars) and PDI (open
circles) and (E) zeta potential of the DDAB:TDB liposomes manufactured by using microﬂuidics]. Results represent the mean ± SD from at least 3
independent experiments.
Molecular Pharmaceutics Article
DOI: 10.1021/acs.molpharmaceut.9b00730
Mol. Pharmaceutics XXXX, XXX, XXX−XXX
D
including FRR, TFR, and initial lipid concentration, all being
shown to be important considerations.1−3,35,40 Therefore,
initially, these parameters were investigated and optimized for
the production of DDAB:TDB.
3.1.1. Lipid Concentration, Flow Rate, and Flow Rate
Ratios. Initial studies considered the impact of initial lipid
concentration of the DDAB:TDB liposomes in terms of size,
PDI, and zeta potential. Previous studies carried out byDavidsen
et al. showed that DDAB:TDB immunological responses were
optimal when the DDAB:TDB molar ratio was ﬁxed at 8:1 (5:1
weight ratio).22 Therefore, variation of the initial lipid
concentration while keeping the DDAB:TDB molar ratio
constant was examined. Initial liposomes concentrations of
0.3, 1, 2, 3, 4, 6, and 24 mg/mL were formulated at constant
microﬂuidic parameters: TFR of 10 mL/min and FRR of 3:1
(Figure 1). When prepared with low lipid concentrations, the
particle sizes were low (approximately 120 nm; Figure 1A).
However, at higher concentrations (1−24 mg/mL) the particle
size was between 250 and 350 nm with no signiﬁcant diﬀerences
(Figure 1A). At all concentrations tested, the DDAB:TDB
liposomes were more heterogeneous in nature (PDI 0.2 to 0.4;
Figure 1B) compared to previously studied liposome
formulations (e.g., see ref 1) where PDIs of below 0.2 were
achieved. In terms of zeta potential, all formulated liposomes
were highly cationic with values between +60 and +75 mV for
initial lipid concentrations from 1 to 24 mg/mL (Figure 1C).
These results show that the DDAB:TDB adjuvants can be
formulated at initial lipid concentration between 1 and 24 mg/
mL with no signiﬁcant diﬀerence in size, PDI, or zeta potential.
Previous studies carried out by Joshi et al. have also shown that
the initial lipid concentration used for the microﬂuidic
production of liposomes is a critical process parameter; for
PC:Chol liposomes it was shown that concentrations above 3
mg/mL gave reproducible physicochemical characteristics of
the formed liposomes, and at concentrations below this the
particle size was increased.3 Forbes et al. also showed that
increasing initial lipid concentration from 0.3 mg/mL to 2 mg/
mL decreased the particle size of neutral liposomes (PC:Chol,
DMPC:Chol, DSPC:chol, and DPPC:chol) and at concen-
trations above 4 mg/mL the particle size plateaued.1
After optimization of the initial DDAB:TDB concentration
for the production of DDAB:TDB, the eﬀect of the TFR and
FRR on particle size, PDI, and zeta potential was evaluated
(panels D and E of Figure 1, respectively). At all three ﬂow rates
tested (5, 10, and 15 mL/min) it can be seen than increasing the
FRR (from 1:1 to 5:1) reduces the liposome size and through
the combined selection of FRR and TFR liposome sizes of 1000
to 160 nm could be prepared (Figure 1D) which, were highly
cationic in nature (Figure 1E). However, at lower FRRs, the
increased particle size was also paired with high PDI (0.7−0.8;
Figure 1D). The smallest particle size and PDI combination was
achieved at a FRR of 3:1 and a TFR of 10 mL/min
(approximately 250 nm; 0.3 PDI; Figure 1D).
The TFR and FRR are important factors to consider when
producing liposomes as they impact on the polarity of the
organic solvent-aqueous phases when mixing within the
micromixer and therefore inﬂuence the physicochemical
attributes of the produced liposomes.2,41 The inﬂuence of the
FRR has been reported previously in several studies, and it is
noted that increases in the aqueous phase during the liposome
production create a narrow solvent stream which consequently
favors the production of small size particles due to reduced
Figure 2.Comparing production methods for liposomal adjuvants. Physicochemical characteristics: (A) particle size and PDI, (B) zeta potential, (C)
H56 antigen loading, and (D) lipid recovery of the DDAB:TDB liposomes produced using either the LHmethod or microﬂuidics at diﬀerent ﬂow rate
ratios (1:1, 3:1, and 5:1). Results represent the mean± SD of at least 3 independent batches. Ag = H56 antigen;−Ag represents without H56 antigen;
+Ag represents with H56 antigen.
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particle fusion.42 Indeed, studies by Kastner et al.,2 Joshi et al.,3
and Forbes et al.1 have shown that increasing the FRR from 1:1
to 5:1 reduced the liposomes size with neutral or anionic
liposomes. Results from another study from Kastner et al. also
demonstrated this ﬂow rate/particle size interaction with
cationic liposomes containing 1,2-dioleoyl-3-trimethylammo-
nium-propane (DOTAP).40 Studies carried out with diﬀerent
microﬂuidic technology also report the eﬀect of the FRR on
particle size.40,43−45 In addition to higher ﬂow rate ratios
producing a smaller solvent stream, the lower organic solvent
concentration may also reduce particle fusion and subsequently
promote the formation of larger particles.40,45 Regarding PDI,
the high values obtained for FRR 5:1 may result from the high
dilution, lower lipid concentrations, lower diﬀusion rates, and
more variable nucleation.40,46
Interestingly, with the manufacture of DDAB:TDB, the speed
at which the particles are manufactured through the system was
shown to impact the liposome size contrary to previous
studies.1,46,47 Generally with microﬂuidics, the rapid mixing
within the microﬂuidic cartridge results in the organic solvent
being diluted very quickly, hindering the formation of large
particles.48 In the case of DDAB:TDB dissolved in 2-propanol
(IPA), high ﬂow rates (>10 mL/min) combined with higher
(>3:1) ﬂow rate ratios may promote better mixing and
nanoprecipitation of DDAB and TDB to form liposomes.
These results highlight the importance of considering the
liposome composition when designing the microﬂuidic
production process. In the case of DDAB:TDB, the particle
size of DDAB:TDB liposomes was controlled by both the FRR
and TFR. On the basis of these results, a TFR of 10 mL/min was
selected for producing liposomes in further studies. This was due
to the ability to produce liposomes in diﬀerent particle size
ranges (combined with the lower PDI) through control of the
FRR.
3.1.2. Antigen Loading and Lipid Recovery of DDAB:TDB
Liposomes. Following optimization of the microﬂuidic method,
DDAB:TDB liposomes were produced using the LH as well as
microﬂuidics (FRR 1:1, 3:1 and 5:1 at TFR 10 mL/min), and
the particle size, zeta potential, antigen loading, and lipid
recovery were measured (Figure 2). DDAB:TDB produced by
the LH were approximately 600 nm in size, with a PDI of 0.3,
and a highly cationic surface charge of +80 mV which promotes
high (>90%) antigen loading ( Figure 1A−C, respectively) in
line with previously reported studies.13,22,49 Addition of 0.1 mg/
mL H56 antigen generally results in a small increase in size and
PDI and reduction in zeta potential as would be expected from
the addition of an anionic subunit antigen to a cationic liposome
formulation (Figure 2). Results from DDAB:TDB produced via
microﬂuidics followed a similar trend, with particle sizes tending
to increase irrespective of initial particle size, and all
formulations showing a high zeta potential and high (>90%)
antigen loading (Figure 2A−C), with no signiﬁcant diﬀerence in
antigen loading across the diﬀerent DDAB:TDB formulations
tested (Figure 2C). In terms of lipid recovery, across all 4
formulations lipid recovery of both DDAB and TDB was high,
with no loss in the microﬂuidic process, ensuring the 5:1 weight
ratio of DDAB to TDB was maintained after production (Figure
2D).
3.2. Liposome and Antigen Movement from the
Injection Site to the Draining Lymphatics. DDAB:TDB
liposomes were labeled with 3H-tritium cholesterol, and theH56
antigen was labeled with 125I; the pharmacokinetic proﬁle of the
DDAB:TDB liposomes manufactured using diﬀerent technol-
ogies after intramuscular injection was studied. All four
liposomal formulations tested contained the same total lipid
and antigen concentration (300 μg of total lipid and 5 μg of H56
per 50 μL dose). The percentage of liposomes (Figure 3A) and
antigen (Figure 3B) at the site of injection (right quadriceps) at
various time points and the area under the curve (AUC) for each
Figure 3.Movement from the injection site of DDAB:TDB liposomal adjuvants to their associated antigen produced by LH andMF. Percentage of (A)
liposomes and (B) antigen retained at the site of injection. Dual labeling of liposomes and antigen by incorporating either 3H-lipid or 125I-antigen was
used for the detection of the liposomes and antigen, respectively, at diﬀerent time points. Liposomes were manufactured using either the LHmethod or
microﬂuidics (FRR 1:1, 3:1, and 5:1). Results represent the mean of 3 mice ± standard deviation.
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formulation were measured. The method of DDAB:TDB (and
the resulting particle size and PDI) does not make a signiﬁcant
diﬀerence on the clearance of the liposomes nor the antigen
from the injection site, as shown by the similar clearance proﬁles
and AUC, which are not signiﬁcantly diﬀerent across the 4
formulations (Figure 3). Drainage from the injection site
followed a similar trend for all 4 liposome formulations, with
between 90% and 100% of the dose remaining after 24 h,
dropping to approximately 50% after 8 days (Figure 3A). These
results for DDAB:TDB produced by the LHmethod (which was
used as our control) are in line with previously published data,
showing that 1 day post injection, DDAB:TDB liposomes begin
to drain steadily from the injection site and on day 8 between
40% and 60% of the initial dose is still detectable there.8 The
depot eﬀect and slow clearance from the injection site of
DDAB:TDB may be attributed to the cationic nature of the
liposomes, which results in the cationic liposomes aggregating
with interstitial proteins and becoming trapped at the injection
site irrespective of their diﬀerence in size. Indeed, previous work
investigating the role of particle size using DDAB:TDB
liposomes prepared via LH and subsequent sonication to
produce small (<200 nm), medium (500−600 nm), and large
(∼1500 nm) vesicles showed no signiﬁcant diﬀerence in the
drainage of the liposomes or their adsorbed antigen from the site
of injection.8 However, this slow clearance of DDAB:TDB may
also be related to their high bilayer rigidity, as substitution of
DDAB with dioctadecyldimethylammonium bromide
(DODAB) did promote a more rapid clearance from the
injection site. The mechanism of action behind the adjuvant
eﬀect of DDAB is also attributed to its cationic nature and its
ability to associate antigens and promote cellular uptake.50,51
Work by Korsholm et al.51 using stimulated immature bone
marrow-derived dendritic cells with ﬂuorescently labeled
ovalbumin (OVA) showed that adsorption of OVA onto
DDAB enhanced the cellular acquisition of the antigen.
Furthermore, inhibition of active cellular processes by OVA
stimulation at 4 °C or by the addition of cytochalasin D reduced
the cellular uptake, suggesting that active actin-dependent
endocytosis is the predominant uptake mechanism.51
Besides the site of injection, the detection of liposomes and
antigen in the lymph nodes was also investigated as vaccine
delivery of antigens to the lymphatics can be important for the
protection against most diseases, such as tuberculosis (TB).52
The popliteal (POP) lymph node is the ﬁrst draining lymph
node where the formulations will move after intramuscular
injection in the mouse quadriceps, followed by the inguinal
lymph node (ILN). These lymph nodes are representative of the
local biodistribution of the formulations, whereas mesenteric
lymph nodes (MLN) were isolated as representation of their
systemic biodistribution. Correlating with the high doses
remaining at the injection site, low levels of DDAB:TDB and
H56 were detected in the POP (less than 0.3% of the initial
vaccine dose administered) with no signiﬁcant diﬀerences
between the four diﬀerent formulations (Figure 4).
3.3. Delivery and Retention of the Cationic Liposomes
to the Draining Lymph Nodes by Exploiting a PEG-
Biotin/Avidin Complex. While DDAB:TDB is known to
promote strong immune responses,53−57 studies based on the
immunization with ﬂuorescent labeled tuberculosis antigen
(Ag85-BESAT-6) and adjuvant (DDAB:TDB) demonstrated
the localization of low amounts of vaccine components in the
draining lymph nodes after subcutaneous immunization.
However, its eﬃcient targeting to the DCs induces potent
Th1 and Th17 responses. Moreover, both antigen and adjuvant
have to target the DCs at the same time in order to elicit Th1/
Th2 responses because previous activation of DCs by free
antigen decreases the generated immune responses.55,58 There-
fore, increasing delivery to the lymphatics may further enhance
immune responses.55,58 Indeed, Mohanan et al. demonstrated
that intralymphatic administration of DDAB:TDB liposomes
Figure 4. Percentage of liposomes (A−C) and antigen (D−F) detected at the lymph node [inguinal (A andD), popliteal (B and E), andmesenteric (C
and F)] after intramuscular injection. Dual labeling of liposomes and antigen by incorporating either 3H-lipid or 125I-antigen was used for the detection
of the liposomes and antigen, respectively, at diﬀerent time points. Liposomes were manufactured using either the LH method (DDAB:TDB LH) or
microﬂuidics (MF) (FRR 1:1, 3:1, and 5:1). Results represent the mean of 3 mice ± standard deviation.
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resulted in signiﬁcantly higher IgG2a and IFN-γ responses
compared to other routes of administration.29 Therefore, to
achieve this, we explored the use of biotinylated liposomes in
combination with predosing of avidin to promote retention of
the vaccine components in the lymphatics.59−61 Previous work
by Medina et al. demonstrated the importance of the injection
order to increase the lymph node targeting, showing better
results when avidin was injected 2 h prior to injection of
biotinylated liposomes.59 Therefore, this dosing strategy was
adopted.
To produce biotinylated DDAB:TDB liposomes, DSPE-
PEG(2000)-biotin was incorporated within the formulation.
DSPE-PEG(2000)-biotin was added to the DDAB:TDB at a 20
mol % ratio and prepared using microﬂuidics TFR 10 mL/min
and FRR 3:1. The 20 mol % ratio was selected as previous
studies have shown that by incorporating 20 mol % of PEG
within DDAB:TDB liposomes, the depot eﬀect can be
blocked.18,19 Therefore, it was hypothesized that the presence
of DSPE-PEG(2000)-biotin on the DDAB:TDB liposomes
would allow them to move from the injection site to the draining
lymphatics, where they would then complex with the avidin and
be retained. As seen previously, antigen was adsorbed onto the
surface of the preformed liposomes. The concentration of lipids
and antigen was adjusted to match the desired in vivo dose (300
μg of total lipid and 5 μg of H56, per 50 μL). Figure 5
summarizes the physicochemical characteristics of the diﬀerent
liposome formulations. DDAB:TDB-biotin liposomes were
signiﬁcantly (p < 0.05) smaller (∼250 nm) in size with an
associated lower PDI (0.25−0.30) when compared to the
DDAB:TDB LH or DDAB:TDB MF (Figure 5A). This PDI,
while slightly higher than would be required for an intravenous
injection, suggests a low level of size heterogeneity which is
useful for robust characterization of the formulation. However,
as shown in Figure 3, variations in particle size alone do not
impact on clearance of the liposomes from the injection site, so a
slightly wider size range would not impact on biodistribution.
The addition of DSPE-PEG(2000)-biotin resulted in a
reduction in zeta potential and antigen loading (+7 mV and
∼60% antigen loading, respectively; Figure 5B). The ability of
the PEG to mask the cationic charge (as shown in Figure 5B)
and thereby circumvent aggregation in the presence of biological
media is shown in Figure 5C−E. Formulations were incubated at
37 °C in 50% FCS and characterized in terms of size, PDI, and
zeta potential. The highly cationic formulation DDAB:TDB LH
aggregates when it is administered and comes in contact with the
serum proteins with the particle size increasing from ∼800 to
∼1800 nm after 3 min, and up to ∼3000 nm after 1 h with no
further change (Figure 5C). Simultaneously, there is an increase
in the PDI (Figure 5D) and a rapid drop in the zeta potential
(+70 to−20mV; Figure 5E) as a result of the cationic liposomes
aggregating with the anionic proteins present in FCS. On the
other hand, the DDAB:TDB-biotin formulation showed a much
lower degree of aggregation, with the vesicle size increasing from
150 to 200 nm in the ﬁrst 3 min, up to 460 nm after 1 h, and
reaching 700 nm after 8 days (Figure 5C). Overall, these
pegylated vesicles show less aggregation (Figure 5C,D) and less
reduction in zeta potential (from +10 to −10 mV; Figure 5E).
On the basis of these results, the ability of the DDAB:TDB-
biotin formulation to avoid aggregation at the injection site was
demonstrated. Therefore, to compare the biodistribution of
Figure 5. Physicochemical characteristic comparison of the DDAB:TDB formulations using LH and microﬂuidics and DDAB:TDB liposomes
incorporating a DSPE-PEG(2000)-biotin. (A) Particle size (bars) and PDI (dots); (B) H56 antigen loading (bars) and zeta potential (diamonds);
stability study of the liposomal formulations under simulated in vivo conditions (50% FCS at 37 °C), (C) particle size, (D) polydispersity and (E) zeta
potential. Results represent the mean ± SD from at least 3 independent experiments.
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these formulations in vivo, DDAB:TDB produced by LH was
compared to DDAB:TDB-biotin alone, or DDAB:TDB-biotin
with mice being predosed with avidin 2 h prior (200 μg/dose;
intramuscularly). Figure 6 shows the percentage of liposomes
Figure 6.Movement from the injection site of DDAB:TDB-biotin liposomes and their associated antigen with or without previous administration of
avidin. Percentage of (A) liposomes and (B) antigen retained at the site of injection. Dual labeling of liposomes and antigen by incorporating either 3H-
lipid or 125I-antigen was used for the detection of the liposomes and antigen, respectively, at diﬀerent time points. Liposomes were manufactured using
either the LH method (DDAB:TDB LH) or microﬂuidics (DDAB:TDB-biotin). Results represent the mean of 3 mice ± standard deviation.
Signiﬁcant diﬀerences are shown as *p < 0.05, **p < 0.01, and ***p < 0.001.
Figure 7. Percentage of biotin-DDAB:TDB liposomes (A−C) and antigen (D−F) detected at the local lymph node [inguinal (A and D), popliteal (B
and E), and mesenteric (C and F)] after intramuscular injection with or without previous administration of avidin. Dual labeling of liposomes and
antigen by incorporating either 3H-lipid or 125I-antigen was used for the detection of the liposomes and antigen, respectively, at diﬀerent time points.
Liposomes were manufactured using either the LHmethod (DDAB:TDB LH) or microﬂuidics (DDAB:TDB-biotin). Results represent the mean of 3
mice ± standard deviation. Signiﬁcant diﬀerences are shown as *p < 0.05, **p < 0.01, and ***p < 0.001.
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Figure 8.Antigen-speciﬁc IgG1 and IgG2c responses after intramuscular immunization using various DDAB:TDB liposomal adjuvants. Five C57BL/6
mice were intramuscularly immunized with H56 combined with diﬀerent adjuvants, and humoral response was analyzed in blood. H56-speciﬁc IgG1
and IgG2c serum response detected by ELISA on sera collected on days 7, 21, and 49 after i.m. immunization. Antibody titers were expressed as the
reciprocal of the highest dilution with an OD value ≥0.1 after background subtraction, and responses from each of the 5 mice are individually plotted
for each time point. Signiﬁcant diﬀerences at the end of the study are shown as *p < 0.05, **p < 0.01, and ***p < 0.001.
Figure 9. Cytokine production in splenocyte and popliteal lymph node (POP) culture supernatants: IL-5, IL-17, and IFN-γ. C57BL/6 mice were
intramuscularly immunized with H56 combined with diﬀerent adjuvants, and spleens and POPs were collected 3 weeks after the last immunization.
Values, expressed as picograms per milliliter, are reported as the mean value ± SD of H56-stimulated of ﬁve animals per group. Signiﬁcant diﬀerences
are shown as *p < 0.05, **p < 0.01, and ***p < 0.001.
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and antigen at the injection site at the chosen time points. The
results show the ability of the DDAB:TDB-biotin liposomes to
move from the injection site more rapidly than DDAB:TDB
liposomes, irrespective of the avidin predosing (Figure 6A). This
is conﬁrmed by comparison of the AUC, which is signiﬁcantly (p
< 0.05) lower with the DDAB:TDB-biotin (approximately
6000−7000% dose·h) compared to the nonbiotinylated
formulation (11 300% dose·h) (Figure 6A). A similar proﬁle
can be seen with the antigen, with more rapid clearance from the
injection site when delivered with the biotinylated liposomes
(irrespective of avidin predosing) (Figure 6B). These results
demonstrate that the presence of the DDAB:TDB-biotin
liposomes, with their reduced size and charge, can move more
rapidly from the injection site. The results also show that the
predosing with avidin 2 h prior to injection does not result in
aggregation at the injection site.
The ability of pegylation to promote the movement of
DDAB:TDB from the injection has been previously shown18,19
with pegylated DDAB:TDB liposomes showing a more rapid
clearance from the injection site to the draining lymphatics.
However, with the biotinylated liposomes we also want
retention at the lymphatics. From Figure 7, it can be seen that
while both biotinylated liposomes may move rapidly from the
injection site, only when mice received a predose of avidin were
the DDAB:TDB-biotin liposomes retained at the lymph nodes,
with up to ∼30% of the DDAB:TDB-biotin liposomes being
detected at the ILN, ∼40% at the POP, and approximately ∼8%
at the MLN (panels A−C of Figure 7, respectively). This is
compared to low (<0.5%) levels of DDAB:TDB-biotin without
predosing of avidin, or DDAB:TDB LH. Again a similar trend
can be seen with the antigen, with high levels of antigen being
recorded at each of the 3 lymph nodes studied only when
delivered with DDAB:TDB-biotin in combination with
predosing of avidin (Figure 7D−F). The MLNs were analyzed
in order to check the systemic distribution of the particles
carrying antigen within the body (Figure 7C,F), and the results
suggest that reaching the MLNs takes longer compared to the
other lymph nodes analyzed in this study. The results also
demonstrate that it is possible to drive the movement of the
liposomal adjuvants and antigen to a range of lymph nodes by
the formation of the avidin/biotin complex.
3.4. DDAB:TDB Vaccine Eﬃcacy Studies. Given that
comparable pharmacokinetic proﬁles were identiﬁed between
the biodistribution of DDAB:TDB produced at the diﬀerent
FRRs (Figure 3), DDAB:TDB produced at a ﬂow rate ratio of
5:1 was tested for vaccine eﬃcacy in vivo. This was compared to
the traditional DDAB:TDB LH lab-scale formulation and the
lymphatic targeting DDAB:TDB-biotin (with and without
avidin predosing). Mice (groups of 5) were immunized three
times with a 2 week interval between immunizations with
DDAB:TDB LH (positive control, traditional method),
DDAB:TDBMF (microﬂuidics), DDAB:TDB-biotin (no avidin
predosing), or DDAB:TDB-biotin/avidin (avidin predosing),
and antibody titers (Figure 8), cytokine responses (Figure 9),
and cytokine production at the injection site (Figure 10) were
measured.
3.4.1. Vaccine Eﬃcacy of DDAB:TDB Liposomal Adjuvants
Produced by Lab-Scale and Scale-Independent Microﬂuidic
Production. In terms of H56-speciﬁc IgG1 (Th2) and IgG2c
(Th1) secretion, when comparing between the DDAB:TDB
formulation prepared by small lab-scale LH method (Figure
8A,B) and those prepared by scale-independent microﬂuidic
processing (Figure 8C,D), both liposomal adjuvants produced
high and comparable antibody responses with no signiﬁcant
diﬀerence at each of the three time points measured.
Antigen-speciﬁc T-cell responses (IL-5, IL-17, and IFN-γ)
were analyzed in the supernatant of restimulated splenocytes
from immunized mice using the ELISA assay (Figure 9). IFN-γ
and IL-17 cytokines are frequently used as markers for the
determination of the vaccine eﬃcacy against TB.62,63
Furthermore, these three cytokines are characteristics of the
immunological DDAB:TDB proﬁle. The DDAB:TDB immuno-
logical ﬁngerprint is distinguished by the production of high
levels of IFN-γ and IL-17 (Th1/Th17 stimulation) and low
levels of IL-5 cytokine (Th2 stimulation), which correlates with
the results shown here (Figure 9A−C). These results conﬁrm
that the DDAB:TDB liposomal adjuvants can be produced by
the rapid and scale-independent microﬂuidics manufacturing
Figure 10.Cytokine production at the injection site (SOI): (A) IFN-γ, (B) IL-5, and (C) IL-17. C57BL/6mice were intramuscularly immunized with
H56 combined with diﬀerent adjuvants, and the sites of injections were excised 3 weeks after the last immunization. Values, expressed as picograms per
miligram, are reported as the mean value± SD of H56-stimulated of ﬁve animals per group. Signiﬁcant diﬀerences are shown as *p < 0.05, **p < 0.01,
and ***p < 0.001.
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process. Interestingly within the lymph nodes, while the cationic
liposomal adjuvants manufactured using microﬂuidics showed
IL-5 responses (Figure 9D) similar to those prepared by the LH
method, DDAB:TDB produced by microﬂuidics prompted
signiﬁcantly (p < 0.05) higher levels of IFN- γ and IL-17
cytokines compared to DDAB:TDB prepared by LH (Figure
9E,F). This may result from subtle diﬀerences in size between
the two formulations which could inﬂuence interactions with
APCs and the production of cytokines in the draining lymph
nodes.8
To investigate this further, the same cytokines were also
analyzed at the site of injection. Supernatants from the injection
site were analyzed by ELISA, and results were normalized by
individual mouse muscle weight. For the cationic liposomal
adjuvants produced by either LH or microﬂuidics, negligible
levels of IL-5 and high production of IL-17 and IFN- γ were
observed (Figure 10). Both manufacturing techniques resulted
in comparable cytokine production, which correlated to the
similar biodistribution proﬁle (Figures 3 and 4), as a result of the
high retention of the vaccine components (liposomes and
antigen) at the injection site due to the cationic nature of the
formulations. These results demonstrate the ability to
manufacture a highly eﬀective liposomal adjuvant formulation
using a scale-independent microﬂuidic production method.
3.4.2. Redirecting and Redirection of DDAB:TDB in the
Draining Lymphatics Using Biotin−Avidin Complexation.
Using this microﬂuidic production method for the cationic
liposomal adjuvants, we investigated the biotin−avidin
DDAB:TDB system as a vaccine adjuvant. Immunization with
the DDAB:TDB-biotin did not result in any notable diﬀerences
in the antibody proﬁles irrespective of the predosing with avidin
with all four formulations promoting similar immune response
proﬁles (Figure 8). When considering the cytokine proﬁles
(Figure 9), target and retention of the DDAB:TDB formulation
to the lymphatics did not improve immune responses with no
notable diﬀerences in cytokine production from stimulated
splenocytes across the four DDAB:TDB formulations (Figure
9A−C). However, when considering cytokine levels induced by
cells isolated from the draining lymph nodes, diﬀerences in
immune response proﬁles can be seen; biotinylated liposomes
combined with avidin predosing resulted in signiﬁcantly (p <
0.05) higher levels of IL-5 compared to the other groups (Figure
9D) and immunization with DDAB:TDB-biotin (with and
without avidin predosing) signiﬁcantly (p < 0.05) reduced IFN-
γ and IL-17 cytokine levels (Figure 9E,F). Considering cytokine
levels at the injection site, IL-5 and IL-17 production was not
signiﬁcantly inﬂuenced by biotinylation of DDAB:TDB (with or
without avidin predosing) (panels A and B of Figure 10,
respectively); however, IFN-γ levels were reduced (Figure 10C),
again irrespective of predosing with avidin. These results show
that while adopting a biotin−avidin complexing strategy can
increase delivery and retention of cationic liposomal adjuvants
and their antigen to local lymph nodes, this does not translate
into improved immune response and may promote a more Th2
biased response. This may have caused trapping of activated
lymphocytes in the nodes and a reduced response. It may also be
a result of the PEG-biotin conjugate used within the
formulation, which allows the liposomes to move from the
injection site by blocking aggregation of the liposomes when
they come in contact with biological moieties. Similar results
were shown when pegylation of DDAB:TDB was investigated as
a mean to block the formation of the depot at the injection site
with Kaur et al. demonstrating that surface pegylation of
DDAB:TDB liposomes was able to allow the cationic liposomes
and antigen to move from the injection site, but reduced
immune responses were noted.18,19 This suggests that the
presence of the PEG moieties incorporated into the liposomal
bilayer reduces immune responses despite helping to promoting
the accumulation of the vaccine components into the lymph
nodes. It has been reported that the incorporation of PEG into
particles reduces particle uptake by macrophages (e.g., see refs
64−66), therefore, it is hypothesized that pegylation of the
DDAB:TDB results in reduced interactions with the APCs and
subsequently reduces its adjuvant activity.
4. CONCLUSIONS
Traditionally, the liposomal adjuvant formulation DDAB:TDB
has been manufactured in a batch scale manner using either the
LH method or high-shear mixing. Production of DDAB:TDB
using these techniques can be an ineﬃcient and time-consuming
process, especially if considered for larger-scale industrial
manufacture. If large-scale production of a TB vaccine is to be
achieved for global immunization, ﬂexible manufacturing
methods that are easily and rapidly translated from bench to
production must be developed. Our results demonstrate the
ability of a microﬂuidic platform to produce DDAB:TDB
liposomal adjuvants with matching physicochemical properties,
pharmacokinetic proﬁles, and immunological activity compared
to DDAB:TDB produced by traditional small batch-scale
methods. Additionally, the use of microﬂuidics allows for the
control of particle size through modiﬁcation of process
parameters. Therefore, microﬂuidic-based manufacture can be
used to support the rapid translation of particulate-based
adjuvants from bench to production. This manufacturing
process was also used to prepare biotin-coated DDAB:TDB
liposomes. By using this formulation, with or without injection
of avidin 2 h in advance, faster clearance from the injection site
was achieved, and predosing with avidin promoted retention of
the biotinylated DDAB:TDB liposomes at the draining lymph
nodes. Interestingly, redirecting the cationic liposomal adju-
vants, and their associated antigen, did not improve immune
responses and may skew the responses to a more Th2 proﬁle.
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